Jyong Biotech Ltd.
MENS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MENS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MENS
Jyong Biotech Ltd. (MENS) is a clinical-stage biopharmaceutical company focused on developing innovative drugs for urinary system diseases, with its core candidate Botreso® for BPH/LUTS having failed a pivotal Phase III trial in the U.S. and facing significant financial constraints.
Key risk: Cash runway insufficient
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Jyong Biotech Ltd. (MENS) is a clinical-stage biopharmaceutical company focused on developing innovative drugs for urinary system diseases, with its core candidate Botreso® for BPH/LUTS having failed a pivotal Phase III trial in the U.S. and facing significant financial constraints.
- Jyong Biotech's core drug candidate Botreso® failed its U.S. pivotal Phase III clinical trial for the primary efficacy endpoint in the intent-to-treat population [sec · filed 2026-05-15].
- As of December 31, 2025, the company had cash and equivalents of $1.2M, a net loss of -$4.7M, negative shareholders' equity of -$29.6M, and total debt of $17.5M [sec].
- The company has built a proprietary R&D platform and holds 31 invention patents and 58 trademarks across multiple territories [sec · filed 2026-05-15].
- All key drug candidates (Botreso®, PCP, IC) are in preclinical or clinical development, with no products approved for commercial sale [sec · filed 2026-05-15].
- The U.S. FDA has granted a meeting request for the new drug development program for API-2, including a Phase I PK study and Phase III clinical trial [sec · filed 2026-05-15].
What works
- The company has built an innovative proprietary R&D platform focused on urinary system diseases, which it believes provides a competitive advantage in drug discovery and development [sec · filed 2026-05-15].
- Jyong Biotech has established integrated in-house capabilities covering all key functions from research to manufacturing, including a pharmaceutical factory in Yilan [sec · filed 2026-05-15].
- The company has a diverse portfolio of drug candidates (Botreso®, PCP, IC) targeting different urinary conditions, providing multiple potential value avenues [sec · filed 2026-05-15].
- It has obtained 31 invention patents and 58 trademarks in 19 and 46 territories respectively, indicating a broad intellectual property strategy [sec · filed 2026-05-15].
What to weigh
- The company's existing cash on hand ($1.2M as of 2025-12-31) is insufficient to meet short-term obligations or long-term plans, including commercialization or future clinical trials [sec · filed 2026-05-15].
- The pivotal Phase III trial for Botreso® in the U.S. failed to show a difference between treatment groups for the primary efficacy endpoint, casting doubt on its regulatory path [sec · filed 2026-05-15].
- All key drug candidates are still in development, and the company has no approved products generating revenue, making it entirely dependent on future regulatory approvals [sec · filed 2026-05-15].
- The company has a history of net losses and negative cash flows, which have adversely affected stockholders' equity and working capital, with accumulated deficit not specified but implied by negative equity of -$29.6M [sec · filed 2026-05-15].
From the filings
Quoted directly from source documents.
Botreso® failed its U.S. Phase III trial
“Our pivotal Phase III clinical trial for Botreso ® in the U.S. failed to show a difference between treatment groups for the primary efficacy endpoint in the intent-to-treat population.”
SEC filings · May 15, 2026
Cash is insufficient for obligations
“Our existing cash on hand will not be sufficient to enable us to meet our short-term obligations or long-term plans, including commercialization of clinical pipeline products, if approved, or initiation or completion of future clinical trials.”
SEC filings · May 15, 2026
No approved products
“We currently have no drug products that are approved for commercial”
SEC filings · May 15, 2026
FDA meeting granted for API-2 program
“The U.S. FDA granted our WRO meeting request and is reviewing our new drug development program for API-2, including Phase I PK study and Phase III clinical trial.”
SEC filings · May 15, 2026
Risks & what to watch (4)›
Key risks
- Cash runway insufficient — Cash of $1.2M as of 2025-12-31 is insufficient for short-term obligations or long-term plans [sec].
- Phase III failure for Botreso® — Pivotal U.S. Phase III trial failed to meet primary efficacy endpoint, jeopardizing regulatory approval [sec · filed 2026-05-15].
- No approved products — All candidates are in preclinical/clinical development; no revenue from commercial sales [sec · filed 2026-05-15].
- Regulatory uncertainty for botanicals — U.S. FDA has rarely approved botanical drug products, adding approval risk [sec · filed 2026-05-15].
What to watch
- Outcome of FDA review for API-2 new drug development program, including Phase I PK study and Phase III clinical trial [sec · filed 2026-05-15].
- Ability to secure additional financing given cash constraints and negative equity [sec].
- Progress of clinical development for other candidates PCP and IC [sec · filed 2026-05-15].
- Regulatory decisions in Taiwan and other territories for Botreso® [sec · filed 2026-05-15].
Sources: SEC filings · Generated August 11, 2026 · How we verify sources →
Run Jyong Biotech Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Jyong Biotech Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
5.4 months
OCF -$3M · Net income -$5M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
12
Total value held
$775K
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 258,760 | $556K |
| geode capital management, llc | 64,232 | $138K |
| millennium management llc | 14,590 | $31K |
| morgan stanley | 6,301 | $14K |
| barclays plc | 5,189 | $11K |
| mirae asset global investments co., ltd. | 3,872 | $8K |
| citigroup inc | 2,787 | $6K |
| bnp paribas financial markets | 1,881 | $4K |
| gf fund management co. ltd. | 1,677 | $4K |
| bell investment advisors, inc | 473 | $1K |
Showing top 10 of 12 institutional holders of Jyong Biotech Ltd.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 0.5%
- Days to cover
- 1.7
- Shares short
- 194,489
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MENS short interestFrequently asked questions
What is the AI investment thesis for Jyong Biotech Ltd.?
Jyong Biotech Ltd. (MENS) is a clinical-stage biopharmaceutical company focused on developing innovative drugs for urinary system diseases, with its core candidate Botreso® for BPH/LUTS having failed a pivotal Phase III trial in the U.S. and facing significant financial constraints.
Who is the CEO of Jyong Biotech Ltd.?
Ms. Fu-Feng Kuo is the chief executive officer of Jyong Biotech Ltd. (MENS).
Where is Jyong Biotech Ltd. headquartered?
Jyong Biotech Ltd. (MENS) is headquartered in New Taipei City, Taiwan.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.